Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines

Authors


  • Present address: Caroline L. Trotter, Department of Social Medicine, University of Bristol, Canynge Hall, Whiteladies Road, Bristol BS8 2PR, UK

  • Editor: Matthias Frosch

Correspondence: Mary E. Ramsay, Immunization Department, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, UK. Tel.: +44 208327 7085; fax: +44 208200 7868; e-mail: mary.ramsay@hpa.org.uk

Abstract

At the end of 2005, six European countries had implemented public immunization campaigns with serogroup C conjugate vaccines, and all had experienced substantial declines in the incidence of serogroup C disease. A quadrivalent ACWY meningococcal vaccine is in use in the USA, but serogroup A is extremely rare in Europe and serogroups Y and W135 are infrequent causes of disease. This paper outlines recommendations on the use of conjugate vaccines in Europe based on the experience with meningococcal C conjugate (MCC) vaccines so far.

Ancillary